We are proud to announce that Zdravlje Leskovac has received the Award for Successful Business in 2022 by the Chamber of Commerce and Industry of Serbia. At the Ceremony held on 9 December, the Chamber of Commerce and Industry of Serbia awarded the traditional Annual Awards to the most successful companies in Serbia...
Zdravlje Leskovac participated for the first time on September 29. at the great “Serbia Business Run“ in Belgrade. This manifestation, which aims to promote healthy lifestyles and running as a great way of recreation for the modern working person, is a series of 5 km business races, which are held in the largest business centers of Serbia and represent the largest sports and corporate event in our country.
Zdravlje is pleased to announce that as of 1st September 2022, Mr. Tsvetomir Yordanov has joined our senior management team as Group Business Development Director, directly reporting to Kiren Naidoo (CEO).
We are pleased to announce that as of 16 August Zdravlje Pharmaceuticals (Bulgaria), a subsidiary of Zdravlje Leskovac, has received a Wholesale Distribution Authorization by the Bulgarian Drug Agency (BDA)....
The Serbian Agency for Medicines (ALIMS) has approved on 02.08.2022 the Marketing Authorisation for Regkirona (regdanvimab) for Serbia with Zdravlje AD Leskovac as the Marketing Authorisation Holder....
Zdravlje is pleased to announce that as of 1st August 2022, Mr. Milan Markicevic has joined our senior management team as Group Finance Director, directly reporting to Kiren Naidoo (CEO)....
As part of the World Exchange Program of Pharmacy and Pharmaceutical Sciences Students (SEP) and the International Pharmacy Students Federation (IPSF) project, which this year marks the 70th anniversary of the first successfully held exchange, Zdravlje, in coordination with the National Association of Pharmacy Students of Serbia, realized a visit...
Zdravlje A.D. (Zdravlje) announces the signing of a license agreement with the Medicines Patent Pool (MPP) for a generic version of nirmatrelvir, the novel oral COVID-19 antiviral medicine (PF-07321332) developed by Pfizer, which is administered in combination with low dose ritonavir (PF-07321332; ritonavir).
Zdravlje is pleased to announce that as of 7 March 2022, Radmila Jakovljevic has joined our team as a Supply and Business Development Manager. Radmila will report directly to Dragan Cirkovic, Commercial Director.
Zdravlje is pleased to announce that as of 7 March 2022, Ms. Tamara Vasojevic has joined our senior management team as Group Human Resources Director, directly reporting to Kiren Naidoo (CEO).
